Диссертация (1139554), страница 53
Текст из файла (страница 53)
Geller M.A., Cooley S., Judson P.L. et al. A phase II study of allogeneic natural killercell therapy to treat patients with recurrent ovarian and breast cancer. // Cytotherapy.2011; 13(1): 98-107.186. Gill S., Porter D.L. CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road. // Expert opinion on biol. therapy. 2014; 14(1): 37-49.187. Girardi M., Oppenheim D.E., Steele C.R.
et al. Regulation of cutaneous malignancyby gammadelta T cells. // Science. 2001; 294: 605-609.188. Gismondi A., Stabile H., Nisti P., et al. Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies. // Front Immunol. 2015; 6: 567.189. Gonzalez S., Groh V., Spies T. Immunobiology of human NKG2D and its ligands. //Current Topics in Microbiology and Immunology. 2006; 298: 121-138.190.
Greten T.F., Jaffee E.M. Cancer vaccines. Clinical oncology. 1999; 17(3): 10471060.276191. Groh V., Bahram S., Bauer S. et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. // Proceedingsof the National Academy of Sciences. 1996; 93: 12445-12450.192. Groh V., Rhinehart R., Randolph-Habecker J. et al. Costimulation of CD8alphabetaT cells by NKG2D via engagement by MIC induced on virus-infected cells. // NatureImmunology. 2001; 2: 255-260.193.
Groh V., Rhinehart R., Secrist H. et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. // Proceedings ofthe National Academy of Sciences. 1999; 96: 6879-6884.194. Groh V., Wu J., Yee C., Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. // Nature. 2002; 419: 734-738.195.
Grupp S.A., Kalos M., Barrett D. et al. Chimeric antigen receptor-modified T cellsfor acute lymphoid leukemia. // New Eng J of Medicine. 2013; 368: 1509-1518.196. Grzywacz B., Kataria N., Kataria N., et al. Natural killer cell differentiation by myeloid progenitors. // Blood. 2011; 117: 3548-3558.197. Gumperz J.E., Litwin V., Phillips J.H., et al. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putativeHLA receptor. // Experimental Medicine.
1995; 181(3): 1133-1144.198. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. // Cell. 2011;144(5): 646-74.199. Hanahan D., Weinberg R.A. The hallmarks of cancer. // Cell. 2000; 100(1): 57-70.200. Hartigan-O’Connor D.J., Poon C., Sinclair E., Mccune J.M. Human CD4+ regulatoryT cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells.
// Immunol Meth. 2007; 319: 41-52.201. Hasmim M., Messai Y., Ziani L., et al. Critical role of tumor microenvironment inshaping NK cell functions: implication of hypoxic stress. // Front Imm. 2015; 6:482.202. Hayakawa Y., Takeda K., Yagita H., et al. IFN-γ-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, a-galactosylceramide // Blood. 2002; 100:1728-33.203. Helm O., Held-Feindt J., Grage-Griebenow E., et al. Tumor-associated macrophagesexhibit pro- and anti-inflammatory properties by which they impact on pancreatic277tumorigenesis.
// International Journal of Cancer. 2014; 135(4): 843-861.204. Huergo-Zapico L., Acebes-Huerta A., Pilar Gonzalez-Rodriguez A. et al. expansionof nk cells and reduction of NKG2D expression in chronic lymphocytic leukemia.correlation with progressive disease. // PLoS One. 2014; 9(10): e108326.205. Hodi F.S., O’Day S.J., McDermott D.F. et al. Improved survival with ipilimumab inpatients with metastatic melanoma. // New Eng J of Med. 2010; 363(8): 711–723.206.
Hoglund P., Brodin P. Current perspectives of natural killer cell education by MHCclass I molecules. // Nature Reviews Immunology. 2010; 10(10): 724-734.207. Holdenrieder S., Eichhorn P., Beuers U. et al. Soluble NKG2D ligands in hepaticautoimmune diseases and in benign diseases involved in marker metabolism. // Anticancer Research. 2007; 27: 2041-2045.208.
Holdenrieder S., Stieber P., Peterfi A. et al. Soluble MICA in malignant diseases. //International Journal of Cancer. 2006; 118: 684-687.209. Holdenrieder S., Stieber P., Peterfi A. et al. Soluble MICB in malignant diseases:analysis of diagnostic significance and correlation with soluble MICA. // Cancer Immunology and Immunotherapy. 2006; 55: 1584-1589.210. Houghton A.N., Gold J.S., Blachere N.E. Immunity against cancer: lessons learnedfrom melanoma. // Current Opinion in Immunology. 2001; 13: 134-140.211. Hsia J.Y., Chen J.T., Chen C.Y. et al. Prognostic significance of intratumoral naturalkiller cells in primary resected esophageal squamous cell carcinoma. // Chang GungMedical Journal.
2005; 28(5): 335-340.212. Iliopoulou E.G., Kountourakis P., Karamouzis M.V. et al. A phase I trial of adoptivetransfer of allogeneic natural killer cells in patients with advanced nonsmall cell lungcancer. // Cancer Immunology and Immunotherapy. 2010; 59: 1781-1789.213. Imada K., Bloom E.T., Nakajima H. et al. Stat5b is essential for natural killer cellmediated proliferation and cytolytic activity. // J Exp Med. 1998; 188: 2067-2074.214. Imai K., Matsuyama S., Miyake S., Suga K., Nakachi K. Natural cytotoxic activityof peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up studyof a general population. // Lancet.
2000; 356(9244): 1795-1799.215. Ishigami S., Natsugoe S., Tokuda K. et al. Prognostic value of intratumoral naturalkiller cells in gastric carcinoma. // Cancer. 2000; 88(3): 577-583.278216. Ito M., Maruyama T., Saito N. et al. Killer cell lectin-like receptor G1 binds threemembers of the classical cadherin family to inhibit NK cell cytotoxicity. // The Journal of Experimental Medicine. 2006; 20;203(2): 289-295.217. Ives N.J., Stowe R.L., Lorigan P., Wheatley K.
Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trialsinvolving 2,621 Patients. // Clinical Оncology. 2007; 25(34): 5426-5434.218. Jamil K.M., Khakoo S.I. KIR/HLA interactions and pathogen immunity. // Biomedicine and Biotechnology. 2011; 298348.219. Jiang S., editor. Regulatory T cells and clinical application. Springer.
2008; 586.220. Jinushi M., Hodi F. S., Dranoff G. Therapy-induced antibodies to MHC class I chainrelated protein A antagonize immune suppression and stimulate antitumor cytotoxicity. // Proc. Natl. Acad. Sci. USA. 2006; 103: 9190–9195.221. Jinushi M., Takehara T., Tatsumi T. et al. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advancedhuman hepatocellular carcinomas. // Hepatology. 2005; 43: 1013-1020.222.
Jinushi M., Vanneman M., Munshi N.C. et al. MHC class I chain-related protein Aantibodies and shedding are associated with the progression of multiple myeloma. //PNAS. 2008; 105: 1285-1290.223. June C.H., Blazar B.R., Riley J.L. Engineering lymphocyte subsets: tools, trials andtribulations. // Nature Reviews Immunology.
2009; 9: 704-716.224. Kabelitz D., Wesch D. Features and functions of gamma delta T lymphocytes: focuson chemokines and their receptors. // Crit Rev Immunol. 2003; 23: 339-370.225. Kabingu E., Vaughan L., Owczarczak B. et al. CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cellsand dependent on natural killer cells.
// Br. J. Cancer. 2007; 96(12):1839-1848.226. Kaminski M.S., Estes J., Zasadny K.R. et al. Radioimmunotherapy with iodide (131)Itositumomab for re- lapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.
// Blood.2000; 96: 1259-1266.227. Kamphuis E., Junt T., Waibler Z., Forster R., Kalinke U. Type I interferons directlyregulate lymphocyte recirculation and cause transient blood lymphopenia. // Blood.2792006; 108: 3253-3261.228. Karakhanova S., Mosl B., Harig S. et al.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
